Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 2/20 | 0.42 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13637139 | 0.75 | NPSR1 (0.33) | TOP2ATOP2BOTUD7B | |
| SCHEMBL18592722 | 0.71 | OTUD7B (0.53) | TOP2ATOP2BOTUD7B | |
| SCHEMBL13625467 | 0.69 | TOP2A (0.37) | TOP2ATOP2B | |
| SCHEMBL9963150 | 0.69 | OTUD7B (0.40) | TOP2ATOP2BOTUD7B | |
| SCHEMBL16750021 | 0.69 | OTUD7B (0.46) | TOP2ATOP2BOTUD7B | |
| SCHEMBL23107538 | 0.69 | OTUD7B (0.46) | TOP2ATOP2BOTUD7B | |
| SCHEMBL23103171 | 0.69 | OTUD7B (0.46) | TOP2ATOP2BOTUD7B | |
| SCHEMBL1698539 | 0.68 | TOP2A (0.67) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| SCHEMBL24716916 | 0.68 | OTUD7B (0.45) | TOP2ATOP2BSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL4019369 | 0.67 | TOP2A (0.50) | TOP2ATOP2BALDH1A1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612200-B2 | Inhibitors of protein kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20090192307-A1 | INHIBITORS OF PROTEIN KINASES | LOCUS PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| US-20070185098-A1 | Inhibitors of protein kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| US-20070185098-A1 | Inhibitors of protein kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192307-A1 | INHIBITORS OF PROTEIN KINASES | MAP3K20, MAP3K1, MAP3K19 | TOP2A 3013/4885TOP2B 3611/4885SMN1; SMN2 4422/4885 |
| US-20070185098-A1 | Inhibitors of protein kinases | MAP3K20, MAP3K1, MAP3K19 | TOP2A 3013/4885TOP2B 3611/4885SMN1; SMN2 4422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.